Published in Medical Letter on the CDC and FDA, December 21st, 2003
Adderall XR is a once-daily, extended-release, mixed salts of a single-entity amphetamine product. Shire Pharmaceuticals Group, plc, (SHPGY) markets the product for the treatment of attention deficit and hyperactivity disorder.
According to NDCHealth, U.S. sales of Adderall XR Capsules were approximately $540 million in the 12 months ended September 30, 2003. Shire received initial FDA approval of this product in October of 2001.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA